Table 1.
Patient characteristics.
| Sample number | Sex | Age at blood sampling | BMI (kg/m2) | Type | Hormonal activity | Basal ACTH (pg/ml) | Basal Cortisol (μg/dl) | Cortisol after LDDST (μg/dl) | UrinaryFree Cortisol (μg/day) | DHEAS(ng/ml) | Tumor diameter (mm) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 60 | 22.2 | NFA | – | 19.5 | 14.5 | 1.3 | 14.2 | 392 | 12 |
| 2 | F | 64 | 27.1 | NFA | – | 8.3 | 8.4 | 1.2 | 38.3 | 140 | 27 |
| 3 | F | 66 | 19.6 | NFA | – | 22.1 | 20.1 | 1.2 | 32.5 | 1532 | 35 |
| 4 | F | 62 | 21.8 | NFA | – | 6.4 | 7.5 | 0.9 | 19.8 | 302 | 18 |
| 5 | F | 57 | 20.6 | CPA | SCS | 2.6 | 6.3 | 5.2 | 21.2 | <50 | 20 |
| 6 | F | 53 | 21.5 | CPA | SCS | 3.2 | 11.3 | 11.9 | 15.4 | 160 | 24 |
| 7 | F | 50 | 23.6 | CPA | CS | 1.0 | 18.3 | 19.8 | 118 | <50 | 27 |
| 8 | M | 72 | 22.4 | CPA | SCS | 11.2 | 10.2 | 5.7 | 33 | 213 | 43 |
| 9 | F | 53 | 27.3 | CPA | SCS | 6.3 | 12.1 | 6.8 | 16.5 | <50 | 30 |
| 10 | M | 67 | 22.3 | PBMAH | SCS | 2.00 | 18.7 | 15.5 | 151 | 188 | R: 39, L: 54 |
| 11 | F | 73 | 28.9 | PBMAH | CS | 1.00 | 19.5 | 24.4 | 155 | <50 | R: 42, L: 31 |
| 12 | F | 77 | 18.2 | PBMAH | SCS | 1.9 | 11.3 | 12.6 | 75.6 | <50 | R: 18, L: 42 |
| 13 | M | 72 | 26.9 | PBMAH | SCS | 5.2 | 10.1 | 8.2 | 54.6 | 115 | R: 58, L: 49 |
| 14 | M | 44 | 22.8 | PBMAH | SCS | 4.8 | 6.08 | 3.15 | 176 | 52 | R: 39, L: 19 |
M, male; F, female; BMI, body mass index; NFA, non-functioning adenoma; CPA, cortisol-producing adenoma; PBMAH, primary bilateral macronodular adrenal hyperplasia; SCS, subclinical Cushing syndrome; CS, Cushing syndrome; LDDST, low-dose dexamethasone suppression test; DHEAS, dehydroepiandrosterone sulfate.